1542770 B.C. Ltd.

Molecule.ai (1542770 B.C. Ltd.) is a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies. The company's platform utilizes autonomous AI agents and predictive analytics to model molecular properties and interactions, aiming to accelerate the discovery of novel therapeutic candidates. In November 2025, the company was acquired by Shuttle Pharmaceuticals Holdings, Inc. to integrate AI-driven drug development capabilities into Shuttle's radiation oncology pipeline. The platform is designed to enhance drug discovery efficiency and provide state-of-the-art tools for molecular modeling and candidate prioritization.